Fesoterodine in randomised clinical trials: An updated systematic clinical review of efficacy and safety

International Urogynecology Journal

Volumn 23, Issue 10, 2012, Pages 1337-1344

  Dell'Utri, Chiara ^a   Digesu, G Alessandro ^a   Bhide, Alka ^a   Khullar, Vik ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Anticholinergics; Efficacy; Fesoterodine; Overactive bladder; Randomised clinical trials; Safety

Indexed keywords

EID: 84868363491     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1696-0     Document Type: Review

References (37)

1. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 21(1):5-26
2. Cartwright R, Srikrishna S, Cardozo L, Robinson D (2011) Validity and reliability of patient selected goals as an outcome measure in overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 22 (7):841-847
3. Irwin DE, Milsom I, Hunskaar S et al (2006) Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: the results of the EPIC study. Eur Urol 50:1306-1314
4. Stewart WE, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States.World J Urol 20:327-336 (Pubitemid 44175300)
5. Chiaffarino F, Parazzini F, Lavezzeri M et al (2003) Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol 43:535-538 (Pubitemid 36528441)
6. Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW (2009) Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 20(7):827-835
7. Digesu GA, Panayi D, Hendricken C, Camarata M, Fernando R, Khullar V (2011) Women's perspective of botulinum toxin treatment for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 22(4):425-431
8. Glavind K, Chancellor M (2011) Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J Pelvic Floor Dysfunct 22 (8):907-917
9. Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF (2010) Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J Pelvic Floor Dysfunct 21(7):847-854
10. Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z (2011). The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J Pelvic Floor Dysfunct Jul 8. [Epub ahead of print]
11. Khullar V, Rovner ER, Dmochowski R, Nitti V et al (2008) Fesoterodine Dose Response in Subjects with Overactive Bladder Syndrome. Fem Urol 71:839-843
12. Cawello W, Auer S, Hammes W et al (2002) Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 365:R110
13. Cole P (2004) Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 29:715-720 (Pubitemid 39279145)
14. Chapple C, Vonkeman H, Hellmis E et al (2004) Fesoterodine a new effective and well tolerated antimuscarinic for the treatment of urgency-frequency syndrome. Results of phase II controlled study. Neurourol Urodyn 598-9.
15. Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW (2009) Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 20(7):827-835
16. Nitti VW, Rovner ES, Bavendam T (2010) Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int 105(9):1268-1275
17. Chapple C, Van Kerebroeck P, Tubaro A et al (2007) Clinical Efficacy, Safety and Tolerability of once-daily Fesoterodine in Subjects with Overactive Bladder. Eur Urol 52:1204-1212 (Pubitemid 47332062)
18. Nitti V, Dmochowski R, Sand P et al (2007) Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome. J Urol 178:2488-2494 (Pubitemid 350052177)
19. Herschorn S, Swift S, Guan Z et al (2010) Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 105:58-66
20. Wyndaele JJ, Golfischer J, Morrow JD et al (2009) Effects of flexible-dose of fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 63(4):560-567
21. Kaplan SA, Schneider T, Foote JE et al (2010) Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, Head-to-head, placebo-controlled trial. BJU Int 107 (9):1432-1440
22. Dmochowski RR, Peters KM, Morrow JD et al (2010) Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 75(1):62-68
23. de Boer TA, Slieker-ten Hove MC, Burger CW, Vierhout ME (2011) The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population. Int Urogynecol J Pelvic Floor Dysfunct 22(5):569-575
24. Ghoniem G, Faruqui N, Elmissiry M et al (2011) Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 22(8):953-961
25. Abrams P, Andersson KE et al (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100(5):987-1006 (Pubitemid 47537675)
26. Michel MC (2008) Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9(10):1787-1796
27. Malhotra B, Sachse R, Wood N (2009) Influence of food on the pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 47(6):384-390
28. Tsao JW, Heilman KM (2003) Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349:2274-2275 (Pubitemid 37485153)
29. Salvatore S, Serati M, Cardozo L et al (2007) Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 197:e8 (Pubitemid 47198192)
30. Brynne N, Dalen P, ALvan G et al (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 63:529-539 (Pubitemid 28277274)
31. Malhotra B, Wood N, Sachse R, Gandelman K (2010) Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 48(5):309-318
32. de Mey C, Mateva L, Krastev Z, Sachse R, Wood N, Malhotra B (2011) Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. J Clin Pharmacol 51(3):397-405
33. Malhotra B, Gandelman K, Sachse R, Wood N (2009) Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol 49(4):477-482
34. Malhotra B, Sachse R, Wood N (2009) Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol 65(6):551-560
35. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC (2009). The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review.
36. Colli E, Parazzini F, Olivieri L et al (2007) Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. Eur Urol 52:525-530 (Pubitemid 46970873)
37. Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A (2010) A prospective observational study of the effects of treatment with extended-release tolterodine on healthrelated quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol 44:138-146